$147,062,009
to ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Advance development of monovalent vaccines against Marburg virus and Sudan Ebolavirus, continuing work that began in 2019.
Addresses critical gaps in medical countermeasures for high-mortality hemorrhagic fevers with pandemic potential; supports U.S. biodefense preparedness.
Signals sustained demand for vaccine manufacturing scale-up, cold-chain logistics, and clinical trial infrastructure for emerging pathogen countermeasures.
Positions U.S. biotech leadership in vaccine development for pathogens where global supply chains remain fragmented; relevant to pandemic preparedness competition.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-24. Cost: $0.003089.
- 2026-05-05STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP)$223.8M
- 2026-05-11THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI$163.1M
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50119C00055_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.